Showing 1 - 2 results of 2 for search 'Ardizoni, A', query time: 0.02s Refine Results
  1. 1
    Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+

    Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ by Govindan, R, Dols, MC, Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Vidal, O, Stewart, D, Ardizoni, A, Weaver, J, Wolfsteiner, M, Reck, M, Talbot, D, Morgensztern, D, Ong, TJ

    Published 2017
    Conference item
  2. 2
    ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

    ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) by Morgensztern, D, Ong, TJ, Dols, MC, Aix, SP, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Vidal, OJ, Stewart, DJ, Fasola, G, Ardizoni, A, Weaver, J, Wolfsteiner, M, Talbot, D, Govindan, R

    Published 2017
    Conference item

Search Tools: